Skip to main content

Table 1 Socio-demographic and clinical characteristics of the patients at baseline

From: Evidence of reduced treatment adherence among HIV infected paediatric and adolescent populations in Nairobi at the onset of the UNAIDS Universal Test and Treat Program

Variable at baseline All patients, n = 319 Pre-UTT patients, n = 122 UTT patients, n = 197
Age at baseline (years): median (IQR) 7.3 (3.0–11.2) 7.4 (3.6–11.2) 7.2 (2.1–11.0)
Gender
 Male 164 (51.4%) 63 (51.6%) 101 (51.3%)
 Female 155 (48.6%) 59 (48.4%) 96 (48.7%)
Primary caregiver
 Both parents 100 (31.3%) 42 (34.5%) 58 (29.4%)
 One parent 175 (54.9%) 63 (51.6%) 112 (56.9%)
 Guardian 44 (13.8%) 17 (13.9%) 27 (13.7%)
HIV-type infection
 HIV-1 308 (96.5%) 118 (96.7%) 190 (96.5%)
 HIV-2 4 (1.3%) 1 (0.1%) 3 (1.5%)
 HIV-1 and HIV-2 7 (2.2%) 3 (3.2%) 4 (2.0%)
 HIV-1 RNA, log10 copies/mL: median (IQR) 4.80 (4.07–5.49) 4.82 (4.10–5.48) 4.72 (3.85–5.52)
CD4+ T-cell count
 Below 200 cells/µL 58 (18.3%) 21 (16.8%) 37 (18.8%)
 200–349 cells/µL 70 (21.7%) 29 (23.4%) 41 (20.8%)
 350–499 cells/µL 94 (29.6%) 34 (28.1%) 60 (30.5%)
 500 or more cells/µL 97 (30.4%) 38 (31.7%) 59 (29.9%)
CD4+ T-cell count, cells/µL: median (IQR) 432 (258–713) 423 (266–741) 466 (243–695)
WHO clinical stage
 Early stage(1 and 2) 122 (38.2%) 45 (36.7%) 77 (39.1%)
 Advanced stage (3 and 4) 197 (61.8%) 77 (63.3%) 120 (60.9%)
1st line ART regimen
 AZT/3TC/NVP 139 (43.7%) 54 (44.3%) 85 (43.1%)
 AZT/3TC/EFV 41 (12.9%) 17 (13.7%) 24 (12.2%)
 ABC/3TC/NVP 58 (18.2%) 20 (16.5%) 38 (19.3%)
 ABC/3TC/EFV 43 (13.3%) 18 (14.6%) 25 (12.7%)
 TDF/3TC/EFV 24 (7.6%) 10 (8.1%) 14 (7.1%)
 ABC/3TC/LPV/r 9 (2.8%) 2 (1.7%) 7 (3.6%)
 AZT/3TC/LPV/r 5 (1.5%) 1 (1.1%) 4 (2.0%)
  1. UTT Universal Test and Treat, IQR interquartile range, WHO World Health Organization, ART antiretroviral therapy, ABC abacavir, 3TC lamivudine, AZT zidovudine, TDF tenofovir, NVP nevirapine, EFV efavirenz, LPV/r lopinavir/ritonavir